Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RABGGTB | P53611 | 5/20 | 0.42 |
| ▸ | RABGGTA | Q92696 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8474581 | 1.00 | MMP2 (0.50) | MMP2NPSR1GAATSHRACHE | |
| SCHEMBL8474592 | 1.00 | MMP2 (0.50) | MMP2NPSR1GAATSHRACHE | |
| SCHEMBL15181729 | 0.87 | MMP2 (0.51) | MMP2NPSR1GAATSHRACHE | |
| SCHEMBL6981947 | 0.83 | MMP2 (0.59) | MMP2NPSR1GAATSHRACHE | |
| SCHEMBL11973569 | 0.83 | MMP2 (0.59) | MMP2NPSR1GAATSHRACHE | |
| SCHEMBL13167999 | 0.80 | TSHR (0.57) | MMP2NPSR1GAATSHRLMNA | |
| SCHEMBL11991816 | 0.80 | TSHR (0.57) | MMP2NPSR1GAATSHRLMNA | |
| SCHEMBL10076668 | 0.80 | GAA (0.47) | MMP2NPSR1GAATSHRLMNA | |
| SCHEMBL10076669 | 0.80 | GAA (0.47) | MMP2NPSR1GAATSHRLMNA | |
| SCHEMBL8695430 | 0.80 | GAA (0.47) | MMP2NPSR1GAATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012120-A1 | Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2009-01-08 | — | — | US | disclosed |
| US-5929252-A | Aziridination of olefins | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012120-A1 | Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines | TET1, TET3, TET2 | MMP2 4733/4885NPSR1 1332/4885GAA 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.